

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/378684265>

# CD8 Dynamics in HIV Infection: A Synoptic Review

Article · March 2024

---

CITATIONS

3

---

READS

12

2 authors:



**Emmanuel Ifeanyi Obeagu**  
Kampala International University (KIU)

1,422 PUBLICATIONS 11,224 CITATIONS

SEE PROFILE



**Getrude Uzoma Obeagu**  
Kampala International University (KIU)

384 PUBLICATIONS 3,307 CITATIONS

SEE PROFILE

## CD8 Dynamics in HIV Infection: A Synoptic Review

\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda.

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda.

\*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, \[emmanuelobeagu@yahoo.com\]\(mailto:emmanuelobeagu@yahoo.com\), ORCID: 0000-0002-4538-0161](#)

### Abstract

The complex interplay between CD8 T cells and Human Immunodeficiency Virus (HIV) infection is a pivotal determinant of disease progression and immune responses. This synoptic review provides an in-depth analysis of CD8 dynamics during HIV infection, elucidating key mechanisms, implications for disease progression, and potential therapeutic interventions. CD8 T cells play a central role in recognizing and eliminating HIV-infected cells, but sustained immune activation may lead to exhaustion, impacting their efficacy. This review synthesizes current knowledge on CD8 functionality, explores the delicate balance between immune activation and exhaustion, and assesses the dynamic changes in CD8 populations across different stages of HIV infection. Furthermore, it delves into the implications of CD8 dynamics for therapeutic interventions, evaluating existing strategies and highlighting emerging approaches. Despite significant progress, challenges persist in understanding the intricate nuances of CD8 responses to HIV. The review concludes by identifying gaps in knowledge and proposing future research directions. This comprehensive synthesis of CD8 dynamics in HIV infection serves as a valuable resource for researchers, clinicians, and policymakers striving to enhance our understanding of the immune responses crucial for combating HIV and developing effective therapeutic interventions.

**Keywords:** *CD8 T cells, HIV infection, immune dynamics, cytotoxicity, viral control, exhaustion, immune activation, immune surveillance, therapeutic interventions.*

### Introduction

Human Immunodeficiency Virus (HIV) remains a formidable global health challenge, necessitating a nuanced understanding of the immune responses orchestrated by various components of the host immune system. Among these components, CD8 T cells emerge as central

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

players in the defense against HIV, wielding the capacity to recognize and eliminate virus-infected cells. The intricate dynamics of CD8 T cells during HIV infection represent a focal point of scientific inquiry, offering insights into the mechanisms that influence disease progression and shape the immune landscape. CD8 T cells, also known as cytotoxic T lymphocytes, are pivotal effectors of the adaptive immune system. Their role in HIV infection extends beyond mere recognition of viral antigens; CD8 T cells actively participate in the immune response by orchestrating cytotoxic activities against infected cells. However, the sustained battle against the resilient HIV poses challenges to CD8 T cell functionality, leading to phenomena such as immune activation and exhaustion.<sup>1-23</sup>

This synoptic review aims to provide a comprehensive exploration of CD8 dynamics in the context of HIV infection. By delving into the functional aspects of CD8 T cells, the review will elucidate the mechanisms underlying their immune responses against HIV. It will also address the delicate equilibrium between immune activation and exhaustion, shedding light on how these dynamics influence disease progression from the acute to the chronic phase.

### **CD8 T Cell Functionality**

CD8 T cells, also known as cytotoxic T lymphocytes (CTLs), play a critical role in the immune defense against Human Immunodeficiency Virus (HIV). The functionality of CD8 T cells is intricately woven into the fabric of the adaptive immune response, serving as sentinels that recognize and eliminate virus-infected cells. CD8 T cells recognize HIV-infected cells through their T cell receptors (TCRs), which bind to viral peptides presented on the surface of infected cells by major histocompatibility complex class I (MHC-I) molecules. This initial interaction is a crucial step in activating CD8 T cells and initiating their effector functions. Upon recognition of infected cells, CD8 T cells unleash cytotoxic activities to eliminate the threat. This includes the release of perforin and granzymes, leading to the induction of apoptosis in the target cell. The ultimate goal is the efficient clearance of virus-infected cells, limiting viral replication and dissemination.<sup>24-39</sup>

CD8 T cells are potent producers of antiviral cytokines, such as interferon-gamma (IFN- $\gamma$ ). These cytokines have diverse effects, including the inhibition of viral replication, modulation of immune responses, and enhancement of antigen presentation. IFN- $\gamma$ , in particular, plays a pivotal role in shaping the antiviral milieu. Successful encounters with HIV lead to the formation of memory CD8 T cells, which confer long-term immunity. These memory cells retain the ability to recognize and respond rapidly to previously encountered viral antigens. Understanding the factors influencing the generation and maintenance of memory CD8 T cells is crucial for vaccine development and long-term immune control. CD8 T cell responses during HIV infection exhibit remarkable heterogeneity. Subsets of CD8 T cells may exhibit different functional profiles, with some cells demonstrating enhanced cytotoxicity, while others prioritize cytokine secretion. Unraveling this heterogeneity is essential for tailoring interventions to maximize antiviral efficacy.

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

The interaction between CD8 T cells and infected cells occurs at the immune synapse, a specialized junction facilitating effective communication. Elucidating the molecular and cellular dynamics of immune synapse formation provides insights into the efficiency and specificity of CD8 T cell responses against HIV.<sup>40-54</sup>

### **Immune Activation and Exhaustion**

The battle between the immune system, particularly CD8 T cells, and Human Immunodeficiency Virus (HIV) is characterized by a delicate interplay between immune activation and exhaustion. While the initial immune response aims to control viral replication, prolonged exposure to the virus can lead to a state of chronic immune activation, eventually culminating in CD8 T cell exhaustion. Persistent exposure to HIV antigens triggers a state of chronic immune activation, characterized by elevated levels of inflammatory cytokines, increased T cell turnover, and heightened expression of activation markers on immune cells. This sustained activation contributes to tissue damage, fosters viral reservoir establishment, and correlates with disease progression. Prolonged antigen exposure during chronic HIV infection can lead to the functional impairment of CD8 T cells, a state known as exhaustion. Exhausted CD8 T cells exhibit reduced effector functions, including diminished cytotoxicity and cytokine production. Key exhaustion markers, such as programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin-domain containing-3 (TIM-3), are upregulated, reflecting a state of T cell dysfunction.<sup>55-67</sup>

Exhausted CD8 T cells often lose their polyfunctional capabilities, compromising their ability to simultaneously perform multiple effector functions. This loss of polyfunctionality is associated with impaired viral control and is a hallmark of the exhaustion process. CD8 T cell exhaustion poses a significant challenge to effective viral control. As exhausted CD8 T cells lose their ability to eliminate infected cells and control viral replication, this state contributes to the establishment of viral reservoirs and perpetuates ongoing viral dissemination. Exhaustion is governed by intricate regulatory pathways, with inhibitory receptors playing a central role. PD-1, TIM-3, and others act as checkpoints that, when engaged by their ligands, transmit inhibitory signals to CD8 T cells, dampening their responsiveness and contributing to the exhaustion phenotype. Strategies to reverse CD8 T cell exhaustion are actively pursued as potential therapeutic interventions. Immune checkpoint blockade, such as anti-PD-1 therapies, has shown promise in restoring CD8 T cell functionality. However, challenges such as identifying optimal timing and combination therapies remain.<sup>68-73</sup>

### **CD8 Dynamics and Disease Progression**

The journey of CD8 T cells through the stages of Human Immunodeficiency Virus (HIV) infection is marked by dynamic changes that intricately shape the landscape of immune responses and disease progression.<sup>74</sup> From the acute phase to the chronic stage, the evolving dynamics of CD8 T cells play a pivotal role in determining the outcome of HIV infection. In the acute phase, CD8 T cells rapidly respond to the initial viral exposure. Effector CD8 T cells target and eliminate HIV-infected cells, contributing to the control of viral replication. The robust CD8 T cell response in

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

this phase is crucial for limiting the establishment of viral reservoirs. During acute infection, there is a notable expansion of CD8 T cell populations, reflecting the urgency of the immune response. As viral replication is controlled, a contraction phase follows, characterized by a reduction in the overall number of activated CD8 T cells. In chronic HIV infection, CD8 T cell dynamics undergo a complex shift. The sustained presence of viral antigens leads to persistent immune activation, contributing to the exhaustion of CD8 T cells. The balance between effector and exhausted CD8 T cell subsets become critical in influencing disease progression.

Heterogeneity in CD8 T cell responses becomes increasingly apparent during chronic infection. Subsets of CD8 T cells may exhibit distinct functional profiles, with some maintaining effector functions, while others display markers of exhaustion.<sup>75</sup> This diversity contributes to the varied outcomes observed in HIV-infected individuals. The effectiveness of CD8 T cell responses in chronic infection significantly influences viral control. Effective CD8 T cell responses can suppress viral replication, while compromised responses contribute to the establishment and persistence of viral reservoirs, a key challenge in HIV management. Some individuals, known as long-term non-progressors, exhibit robust CD8 T cell responses that effectively control viral replication for an extended period. Understanding the unique dynamics and characteristics of CD8 T cells in these individuals holds potential insights for therapeutic strategies. Antiretroviral therapy (ART) has revolutionized the management of HIV infection. While ART effectively suppresses viral replication, its impact on CD8 T cell dynamics and functionality is an area of ongoing investigation. Optimizing CD8 T cell responses is crucial for achieving long-term immune control, even in the presence of effective ART.

### **Implications for Therapeutic Interventions**

The dynamic interplay between CD8 T cells and Human Immunodeficiency Virus (HIV) infection has profound implications for therapeutic interventions.<sup>76</sup> As CD8 T cells are central effectors in the immune response against HIV, understanding their dynamics opens avenues for targeted strategies aimed at optimizing antiviral responses. Antiretroviral therapy remains the cornerstone of HIV management, effectively suppressing viral replication and preserving immune function. While ART primarily targets viral replication, its impact on CD8 T cell dynamics is significant. Optimizing ART regimens to minimize immune activation and maintain CD8 functionality is a crucial consideration. Immune checkpoint blockade, particularly targeting programmed cell death protein 1 (PD-1) on CD8 T cells, has emerged as a promising therapeutic avenue. Blocking inhibitory receptors aims to alleviate CD8 T cell exhaustion, restoring their effector functions. Clinical trials exploring the efficacy and safety of immune checkpoint inhibitors in HIV are ongoing.

Modulating cytokine signaling represents another therapeutic strategy. Interleukin-7 (IL-7) has shown potential in enhancing CD8 T cell expansion and function. However, careful consideration of dosing and potential side effects is crucial to ensure therapeutic efficacy without inducing

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

excessive immune activation. Developing an effective HIV vaccine remains a formidable challenge. Insights into CD8 T cell dynamics inform vaccine strategies aimed at eliciting robust and durable CD8 responses. Novel vaccine platforms, including mRNA vaccines and viral vectors, are being explored to stimulate potent CD8 T cell immunity. Recognizing the multifaceted nature of CD8 T cell responses, combination therapies are under investigation. Integrating immune checkpoint blockade with antiretroviral drugs or other immunomodulatory agents aims to synergize therapeutic effects, maximizing CD8 T cell functionality. Genetic engineering approaches, such as chimeric antigen receptor (CAR) T cells, are being explored in the context of HIV. Engineering CD8 T cells to express receptors with enhanced antiviral specificity holds promise for redirecting their activity against infected cells. Adjuvant therapies that target inflammation and immune activation are gaining attention. Agents that modulate Toll-like receptor signaling or inflammasome activation may help to mitigate chronic immune activation, preserving CD8 T cell function. Recognizing the heterogeneity in CD8 T cell responses, personalized medicine approaches are being explored. Tailoring therapeutic interventions based on individual immune profiles aims to optimize outcomes and minimize potential adverse effects.<sup>75</sup>

## Conclusion

The intricate dance between CD8 T cells and Human Immunodeficiency Virus (HIV) unfolds as a dynamic saga, shaping the course of infection, immune responses, and therapeutic possibilities. This synoptic review has traversed the realms of CD8 dynamics during HIV infection, illuminating key aspects that hold implications for our understanding of pathogenesis and the development of targeted interventions. The functional prowess of CD8 T cells, from antigen recognition and viral clearance to memory formation, underscores their pivotal role in orchestrating the immune response against HIV. However, this journey is not without challenges. Chronic immune activation, a consequence of persistent viral exposure, can lead to the exhaustion of CD8 T cells, compromising their effectiveness and contributing to disease progression.

## References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023;

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

- 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
  6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
  7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
  8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
  9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
  10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
  11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
  12. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
  13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.  
[https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
  14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
  15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

- <links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf>
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
  17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. <links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf>.
  18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130. <links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf>.
  19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
  20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4. <links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf>
  21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: <10.22192/ijcrms.2017.03.02.005>
  22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
  23. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139. <links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf>.
  24. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences*.

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

2022;2(3):128-134.

<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.

25. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022;29-34.
26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015).
28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014) [https://www.academia.edu/download/54317126/Haematological\\_indices\\_of\\_malaria\\_patients\\_coinfected\\_with\\_HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
32. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences*. 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
33. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137)

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

[links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://epjournals.com/journals/EJI/links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).

34. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
35. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
36. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases*. 2022;10(4):1-7.
37. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
38. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):42-57. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
40. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
41. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://epjournals.com/journals/EJI/links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
42. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

43. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretroviral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8. DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretroviral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.com/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretroviral-therapy-a-review-of-prevalence.pdf).
44. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13. DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002)  
[links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
45. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508aebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
46. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910. [https://www.academia.edu/download/38320134/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
47. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
48. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):28-31.
49. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP)*. 2023;3(2):64-67.
50. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
51. Ibebuikwe JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
52. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
53. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

54. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
55. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
56. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
57. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-59.
58. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
59. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
60. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
61. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
62. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
63. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
64. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
65. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
66. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46):

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13

- e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
67. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
  68. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep*. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
  69. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
  70. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.
  71. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res*. 2023;10(10):56-62.
  72. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
  73. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
  74. Chan YT, Cheong HC, Tang TF, Rajasuriar R, Cheng KK, Looi CY, Wong WF, Kamarulzaman A. Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. *Biomedicines*. 2022;10(11).
  75. Gerlach C, Rohr JC, Perié L, Van Rooij N, Van Heijst JW, Velds A, Urbanus J, Naik SH, Jacobs H, Beltman JB, de Boer RJ. Heterogeneous differentiation patterns of individual CD8<sup>+</sup> T cells. *Science*. 2013;340(6132):635-639.
  76. Perdomo-Celis F, Taborda NA, Rugeles MT. CD8<sup>+</sup> T-cell response to HIV infection in the era of antiretroviral therapy. *Frontiers in immunology*. 2019; 10:1896.

**Citation:** Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*, 2024; 2(1): 1-13